Frequently Asked Questions about Edgewise Therapeutics, Inc. (EWTX)

Name: Edgewise Therapeutics, Inc. (EWTX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Edgewise Therapeutics, Inc. (EWTX) do?

Accepted Answer

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dyst...

Question 2

Is Edgewise Therapeutics, Inc. (EWTX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of EWTX reveals an Altman Z-Score of 68.30 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if EWTX fits their risk profile.

Question 3

What is the current P/E ratio for EWTX?

Accepted Answer

As of the latest trading session, Edgewise Therapeutics, Inc. (EWTX) has a trailing P/E ratio of -19.56.

Question 4

Who is the CEO of Edgewise Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Edgewise Therapeutics, Inc. is Kevin Koch.

Question 5

What was EWTX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Edgewise Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does EWTX pay a dividend?

Accepted Answer

Edgewise Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does EWTX have?

Accepted Answer

In its latest reporting period, Edgewise Therapeutics, Inc. generated $-0.14B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Edgewise Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Edgewise Therapeutics, Inc. (EWTX) is currently 6.29.

Question 9

What is the Price-to-Sales (P/S) ratio of EWTX?

Accepted Answer

Based on trailing twelve-month data, Edgewise Therapeutics, Inc. (EWTX) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Edgewise Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Edgewise Therapeutics, Inc. (EWTX) has a Return on Equity (ROE) of -31.97%, representing its profitability relative to shareholder equity.

Period	Gross Profit	Op. Income	Net Income	EPS
2025-12	-2.3M	-191.4M	-167.8M	-1.63
2024-12	0	-158.8M	-133.8M	-1.45
2023-12	0	-114.4M	-100.2M	-1.57
2022-12	0	-71.7M	-67.6M	-1.26
2021-12	0	-43.2M	-42.8M	-0.86

Period	Gross Profit	Op. Income	Net Income	EPS
2025-12	-2.3M	-191.4M	-167.8M	-1.63
2024-12	0	-158.8M	-133.8M	-1.45
2023-12	0	-114.4M	-100.2M	-1.57
2022-12	0	-71.7M	-67.6M	-1.26
2021-12	0	-43.2M	-42.8M	-0.86